The Copenhagen site is one of the most active biologics facilities in the AGC Biologics network.
Onsite, we operate multiple mammalian and microbial cGMP manufacturing lines at a variety of scales, and the facility also offers a great depth of technological flexibility for projects ranging from pre-clinical through commercial production.
The core teams of scientists here have strong scientific acumen and have been working together to develop and manufacture biologics for several decades. This expertise and experience mean your product is being managed by some of the best in the business.
Expanded capacity in 2023: Coming online in June, we have more than doubled our mammalian cell culture manufacturing capacity. Learn more.
Andrea C. Porchia
